A person enrolled in a clinical trial receives the COVID vaccine. Employers' vaccine mandates came under scrutiny during the ...

ALK will also pay up to $320m in milestone payments to ARS in the deal, which sees the latter keep rights in the US, ...

Revenue growth is due to growth in Teva's US generics business, the company's main market, among other things due to sales of ...

I have long held the belief that digital therapeutics will be prescribed alongside drugs to improve patient outcomes, leading ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $25.00. The company’s shares closed last Friday ...

Pennsylvania was involved in a coalition of 50 states and territories that have settled with the generic prescription drug ...

Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their ...

In terms of liquidity and interest, the mean open interest for Teva Pharmaceutical Indus options trades today is 8263.67 with ...

In this episode of Denatured, Lori and guests from Teva Pharmaceuticals and TOWER Capital discuss the opportunties, regulatory challenges and uncertainty surrounding AI.

The global market for peptide therapies is projected to grow at an outstanding compound annual growth rate (CAGR) of 10.8% ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q3 2024 Earnings Call Transcript November 6, 2024 Teva Pharmaceutical ...